ADA 2012 Diabetes Guidelines for type 2 diabetes> | AMLN Message Board Posts

Amylin Pharmaceuticals, Inc.

  AMLN website

AMLN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  73131 of 74102  at  6/8/2012 2:52:18 PM  by

seemiketalk


ADA 2012 Diabetes Guidelines for type 2 diabetes>

http://care.diabetesjournals.org/content/35/Supplement_1/S11.full
 
 

2. Therapy for type 2 diabetes.

Recommendations.
  • At the time of type 2 diabetes diagnosis, initiate metformin therapy along with lifestyle interventions, unless metformin is contraindicated. (A)

  • In newly diagnosed type 2 diabetic patients with markedly symptomatic and/or elevated blood glucose levels or A1C, consider insulin therapy, with or without additional agents, from the outset. (E)

  • If noninsulin monotherapy at maximal tolerated dose does not achieve or maintain the A1C target over 3–6 months, add a second oral agent, a GLP-1 receptor agonist, or insulin. (E)

Prior expert consensus statements have suggested approaches to management of hyperglycemia in individuals with type 2 diabetes (98). Highlights include intervention at the time of diagnosis with metformin in combination with lifestyle changes (MNT and exercise) and continuing timely augmentation of therapy with additional agents (including early initiation of insulin therapy) as a means of achieving and maintaining recommended levels of glycemic control (i.e., A1C <7% for most patients). As A1C targets are not achieved, treatment intensification is based on the addition of another agent from a different class. Meta-analyses (98a) suggest that overall, each new class of noninsulin agents added to initial therapy lowers A1C around 0.9–1.1%. The overall objective is to safely achieve and maintain glycemic control and to change interventions when therapeutic goals are not being met.

ADA and EASD have partnered on new guidance for individualization of use of medication classes and combinations in patients with type 2 diabetes. These guidelines, to be published in early 2012, will be less prescriptive than prior algorithms, and will discuss advantages and disadvantages of the available medication classes as well as considerations for their use. For information about currently approved classes of medications for treating hyperglycemia in type 2 diabetes, see Table 10.

View this table:
Table 10

Noninsulin therapies for hyperglycemia in type 2 diabetes: properties of selected glucose-lowering drugs that may guide individualization of therapy




 
     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 546 (updated 24hrs)
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help    Advertise
Not a member yet? What are you waiting for? Join Now
Want to contribute? Support InvestorVillage by donating
2003-2014 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.

Loading...